Ambrosia launches revolutionary “Direct-to-Apple Watch” NightRider BluCon for Continuous Glucose Monitoring

SAN FRANCISCO, July 19, 2019 /PRNewswire/ — Ambrosia Systems, a fast growing medical  technology company, today announced the launch of the next version of NightRider BluCon. The new NightRider BluCon works with Apple watch to display glucose readings from the FreeStyle Libre and Libre Pro sensors on Apple watch without the phone. This will help parents of the millions of Type 1 diabetic children monitor their children’s glucose levels when the child is away. Currently, parents don’t have a way to know the current glucose levels of their Type 1 diabetic child if he or she is not carrying their phone, which most schools don’t allow. Also, it is difficult for young children to carry their phone all the time.

After the initial setup of Ambrosia’s NightRider and LinkBluCon app on the iPhone, the user can change the mode to Apple Watch on LinkBluCon’s settings screen, this will switch the NightRider connection from the iPhone to Apple Watch and will start displaying glucose readings on Apple Watch without the phone. If Apple Watch has a cellular connection, parents can install Ambrosia’s FollowBluCon app on their phone and, after setup, will be able to see glucose readings updates of their child every five minutes.

Disclaimer:

Ambrosia apps are not FDA approved and should not be used to make medical decisions.
FreeStyle Libre is a trademark of Abbott Diabetes Care Inc. Ambrosia Systems Inc. does not have any kind of relationship with Abbott Diabetic Care or Abbott Laboratories.

About Ambrosia Systems

Ambrosia Systems is a fast growing medical technology company focused on building easy to use and affordable technology solutions for patients, providers, payers and caregivers. The NightRider BluCon is currently in use in more than 100 countries with FreeStyle Libre, FreeStyle Libre 2 and FreeStyle Libre Pro sensors. To learn more, visit www.ambrosiasys.com

Media Contacts: Mia Flaherty, Ambrosia Systems Inc. mia.flaherty@ambrosiasys.com, +1-415-293-8242

View original content to download multimedia:http://www.prnewswire.com/news-releases/ambrosia-launches-revolutionary-direct-to-apple-watch-nightrider-blucon-for-continuous-glucose-monitoring-300887904.html

SOURCE Ambrosia Systems

Staff

Recent Posts

Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates

ELI-002 2P clinical immunogenicity data were accepted for a poster presentation at the AACR Annual…

2 hours ago

Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update

AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or…

2 hours ago

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

-- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by…

2 hours ago

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading…

2 hours ago

SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics Reports Full Year…

2 hours ago

Vision Sensing Acquisition Corp. Announces Intention to Extend Period to Consummate Initial Business Combination to May 3, 2024

MIAMI, March 29, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW)…

2 hours ago